Close menu




September 21st, 2020 | 08:38 CEST

Snowflake, Wallstreet:Online, Commerzbank - Investors reward success

  • Investments
Photo credits: pixabay.com

Scalable business models are popular with investors. A specific infrastructure, service or product can be offered by the provider to an increasing number of customers at no noticeable additional cost. These often exponential growth rates make the providers' coffers ring. The stock markets usually reward the rosy outlook with strong price gains. If, on the other hand, the growth story is missing, investors can already be satisfied with a sideways movement.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: US8334451098 , DE000A2GS609 , DE000CBK1001

Table of contents:


    Share price doubles since IPO

    Last Wednesday, the newcomer to the stock market, Snowflake, drew attention to himself in an impressive way. The shares of the cloud data platform from San Mateo, California, started the day of the IPO in New York with a price increase of over 100%. This was even though the sales range was briefly increased from USD 75 to 85 and then fixed at USD 120. Measured by the inflow of funds of around USD 3.4 billion, Snowflake is the largest US IPO to date this year. The company is currently valued at almost USD 70 billion.

    According to press reports, both SAP rival Salesforce, through its investment arm, and Berkshire Hathaway, the company of star investor Warren Buffett, each invested USD 250 million at the IPO.

    The company's business model is inspiring many. Snowflake enables customers to consolidate data into a single cloud source, gain real-time business insight, build data-driven applications and share data (multi-cloud strategy, cross-cloud approach). The share closed the week at USD 240.

    The 100 Euro mark may soon be broken

    With almost 290 million page impressions, the Wallstreet:Online group is by far the largest publisher-independent financial portal operator in the German-speaking world and the largest financial community. Besides, the group has been operating Smartbroker, its online broker, since the beginning of 2020.

    Last week, w:o significantly raised its forecast for the current financial year. In the area of financial portals, the Berliners are benefiting from rising user numbers and advertising revenues. Smartbroker's growth is also much more dynamic than expected at the beginning of the year. In May 2020, the company's planning still envisaged the acquisition of 60,000 customers, but now the target is over 83,000 new customers.

    The improved outlook caused the share to rise by 6.6% to EUR 84.40 on Friday. It is to be expected that the analyst firms will soon raise their earnings estimates and subsequently their price targets significantly. The average price target should rise from the current EUR 90 to well over EUR 100.

    Investors can consider themselves lucky: The share has two strongly growing and even mutually stimulating, scalable business areas. There can therefore be no doubt that w:o can continue to surprise positively in the future.

    Still in sideways mode

    Commerzbank AG is one of the leading banks for private and corporate customers in Germany. The company has been reinventing itself for many years. The takeover of the online broker Comdirect in the summer was certainly important in this process. The new Commerzbank supervisory board chairman Hans-Jörg Vetter made it clear last week: "Commerzbank is not a restructuring case, but Commerzbank must become more efficient.

    Last week, the share lost a good 7% and left XETRA trading at EUR 4.48 on Friday. The group currently has around EUR 5.6 bn on the stock exchange. The publication of the nine-month figures is scheduled for November 5, 2020.

    According to a Friday announcement, ECB insiders reported that banks in the euro area are facing an imminent end to the de facto dividend freeze caused by the Corona crisis. This was, however, irrelevant for the low yielding stock. The most recent dividend paid out was EUR 0.20 for the 2018 financial year. The consensus of the 12 analysts is that a dividend of EUR 0.04 per share will not be paid out until the 2021 financial year, i.e. in the calendar year 2022.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read